NCT02688088View on ClinicalTrials.gov

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

February 4, 2018

Study Completion Date

January 6, 2021

Conditions

Neoplasm Metastasis

Interventions

DRUG

Drug Cocktail

Administered orally

DRUG

Abemaciclib

Administered orally

Trial Locations (5)

46202

IU Simon Cancer Center, Indianapolis

66160

University of Kansas Hospital, Fairway

75230

Mary Crowley Cancer Research Center, Dallas

80218

Sarah Cannon Research Institute at HealthOne, Denver

78229-3307

South Texas Accelerated Research Therapeutics, LCC, San Antonio

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02688088 - A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body | Biotech Hunter | Biotech Hunter